| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FKBP4 |
| Uniprot No | Q02790 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-459aa |
| 氨基酸序列 | MTAEEMKATESGAQSAPLPMEGVDISPKQDEGVLKVIKREGTGTEMPMIG DRVFVHYTGWLLDGTKFDSSLDRKDKFSFDLGKGEVIKAWDIAIATMKVG EVCHITCKPEYAYGSAGSPPKIPPNATLVFEVELFEFKGEDLTEEEDGGI IRRIQTRGEGYAKPNEGAIVEVALEGYYKDKLFDQRELRFEIGEGENLDL PYGLERAIQRMEKGEHSIVYLKPSYAFGSVGKEKFQIPPNAELKYELHLK SFEKAKESWEMNSEEKLEQSTIVKERGTVYFKEGKYKQALLQYKKIVSWL EYESSFSNEEAQKAQALRLASHLNLAMCHLKLQAFSAAIESCNKALELDS NNEKGLFRRGEAHLAVNDFELARADFQKVLQLYPNNKAAKTQLAVCQQRI RRQLAREKKLYANMFERLAEEENKAKAEASSGDHPTDTEMKEEQKSNTAG SQSQVETEALEHHHHHH |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FKBP4重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *FKBP52. a novel BCL-2 binding protein, accelerates the prosurvival function of BCL-2 and promotes cell proliferation*
**作者**: Pei, H., Li, C., Adereth, Y., et al.
**摘要**: 该研究探讨了重组FKBP4(FKBP52)蛋白与BCL-2的相互作用，发现FKBP4通过增强BCL-2的抗凋亡功能促进细胞存活，并可能在前列腺癌进展中发挥作用。实验利用重组人FKBP4蛋白验证其与BCL-2的结合及对细胞增殖的影响。
2. **文献名称**: *Structure and functional analysis of the human FKBP52 immunophilin*
**作者**: Davies, T.H., Ning, Y.M., Sánchez, E.R.
**摘要**: 研究通过重组表达人FKBP4蛋白，解析其与Hsp90复合物的相互作用机制，揭示FKBP4通过TPR结构域介导Hsp90依赖性激素受体(如雄激素受体)的活性调控，为类固醇信号通路提供分子机制依据。
3. **文献名称**: *Recombinant FKBP52 reveals chaperone activity for tau protein*
**作者**: Yamazaki, M., Matsuo, S., Shimizu, T., et al.
**摘要**: 该文献报道了重组FKBP4蛋白在体外的分子伴侣功能，证明其能够抑制tau蛋白的错误折叠和聚集，提示FKBP4可能参与神经退行性疾病中蛋白质稳态的维持。实验利用大肠杆菌表达系统获得高纯度重组蛋白。
---
以上文献涵盖了FKBP4在癌症信号、结构功能及神经疾病中的研究，均涉及重组蛋白的应用分析。如需扩展，可进一步检索PubMed或Web of Science数据库。
FKBP4. also known as FKBP52. is a member of the FK506-binding protein (FKBP) family characterized by its peptidyl-prolyl isomerase (PPIase) activity. These proteins play critical roles in protein folding, cellular signaling, and regulation of steroid hormone receptor complexes. FKBP4 specifically interacts with heat shock protein 90 (Hsp90) through its tetratricopeptide repeat (TPR) domain, forming a chaperone complex essential for the maturation and functional activation of hormone receptors, including glucocorticoid, androgen, and progesterone receptors. This interaction highlights its importance in steroid-responsive pathways and stress response mechanisms.
Recombinant FKBP4 is engineered for experimental and therapeutic applications, enabling studies on its structure-function relationships and interactions with partner proteins. Structurally, FKBP4 contains three FKBP12-like domains and a calmodulin-binding region, which contribute to its PPIase activity and ability to modulate calcium signaling. Post-translational modifications, such as phosphorylation, further regulate its activity in cellular processes like cell cycle progression and apoptosis.
Dysregulation of FKBP4 has been implicated in hormone-related diseases, neurodegenerative disorders, and cancer. Overexpression in certain cancers correlates with poor prognosis, suggesting roles in tumor progression. Recombinant FKBP4 serves as a tool for drug discovery, particularly in targeting Hsp90-FKBP4 complexes to disrupt oncogenic pathways. While classical immunosuppressants like FK506 primarily bind FKBP12. research on FKBP4-specific inhibitors could yield therapies for hormone-resistant cancers or neurodegenerative conditions linked to protein misfolding. Its dual roles in chaperone systems and signaling networks make FKBP4 a compelling target for both basic research and translational applications.
×
